Regeneron Ventures and Deerfield Management led a $66m Series B round in Actio Biosciences.

Regeneron Ventures and Deerfield Management, a private equity firms, led a $66m Series B round in Actio Biosciences, a clinical-stage biotechnology company, with participation from Canaan, Droia Ventures and Euclidean Capital. “We have made tremendous progress across our pipeline – executing a precision medicine strategy that targets the root causes of disease through genetically informed drug development," David Goldstein, Actio Co-Founder and CEO.